KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

High-Dose Methotrexate in Children and Young Adults With ALL and Lymphoblastic Lymphoma: Results of the Randomized Phase III Study UKALL 2011.

Amy A Kirkwood, Nicholas Goulden, John Moppett, Sujith Samarasinghe, Rachael Hough, Clare Rowntree, Sarah Lawson, Pam Kearns, Anna Lawson, Ajay Vora

J Clin Oncol 43(15) 1810-1823

PMID40193822
PMCIDPMC12084015
DOI10.1200/JCO-24-01851
发表日期2025-04-07
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

PURPOSE: UKALL 2011 randomly assigned children and young adults (younger than 25 years) with ALL or lymphoblastic lymphoma. The aims were to reduce induction toxicity (randomization 1 [R1]), CNS relapse risk (randomization 2 [R2]-interim maintenance [R2IM]), and maintenance morbidity (R2pulses). METHODS: R1 compared induction dexamethasone (dex) for 28 days (6 mg/m2; standard) with 14 days (10 mg/m2; short). R2 was a factorial randomization resulting in four arms: high-dose methotrexate (HDM) with pulses, HDM without pulses, standard interim maintenance (SIM) with pulses (standard of care), and SIM without pulses. The primary end points were reduction in steroid-related toxicity (R1), CNS relapse rate (CNSR, R2IM), and bone marrow relapse rate (BMR, R2pulses; ALL only, noninferiority margin 5%). Event-free survival (EFS) was an additional primary end point for both randomizations. RESULTS: Of 2,750 eligible patients registered between April 2012 and December 2018, 1,902 were randomly assigned to R1 and 1,570 to R2. Median follow-up is 99 (R1) and 87 months (R2). There were no differences in steroid-related toxicity between short and standard dex (23.8% v 25.5%; P = .41) and CNSR between SIM and HDM (0.98 [95% CI, 0.65 to 1.49]; P = .94; 5-year rates: SIM 5.3% and HDM 5.5%). EFS was no different between R1 and R2IM arms. BMR in the no pulses arm was noninferior (+1.7% increase at 5 years [95% CI, -1.5 to 4.1]; hazard ratio [HR], 1.19 [95% CI, 0.87 to 1.62]; P = .27). Although the EFS in the no pulses arm was inferior (1.34 [95% CI, 1.05 to 1.73]; P = .021), this was not significant for relapse (HR, 1.24 [95% CI, 0.96 to 1.62]; P = .10). CONCLUSION: Shorter duration of induction dex does not reduce steroid-related toxicity and HDM does not improve CNSR within a UKALL treatment backbone. Omission of pulses is noninferior for BMR.

KM 提取结果

1 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure3 个面板

FIG 2.

(A) EFS, (B) OS, and (C) relapse risk in trial overall. EFS, event-free survival; OS, overall survival.

A

EFS

FIG 2. · Panel A

complete 待 EXE 对齐 预期 1 条 已提取 1 条

Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

OS

FIG 2. · Panel B

complete 待 EXE 对齐 预期 1 条 已提取 1 条

Panel B 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

cumulative incidence of relapse

FIG 2. · Panel C

complete 待 EXE 对齐 预期 1 条 已提取 1 条

Panel C 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.CONSORT diagram. a Died (N = 1), relapsed (N = 3), and AEs (N = 4). b Died (N = 1), relapsed (N = 4), and treatment change because of higher-risk disease (N = 3). c Osteonecrosis (N = 1), vincristine neurotoxicity (N = 2), diabetes (N = 1), and neuropathy/cardiac failure and foot ulcer (N = 1). d Relapsed (N = 8), developed HLH (N = 1), off trial because of AEs (N = 1), and unknown reason (N = 1). AE, adverse event; Dex, dexamethasone; HDM, high-dose methotrexate; HLH, hemophagocytic lymphohistiocytosis; IM, interim maintenance; NOS, not otherwise specified; R1, randomization 1; R2, randomization 2; SIM, standard interim maintenance; SOC, standard of care.
非 KM Figure
FIG 3.(A) EFS by R1 arms. (B) EFS by R2IM arms. (C) EFS by R2 pulses arms. EFS, event-free survival; HDM, high-dose methotrexate; R1, randomization 1; R2, randomization 2; SIM, standard interim maintenance.
非 KM Figure